Mechanisms of Resistance to KRASG12C Inhibitors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
KRAS is one of the most common human oncogenes, but concerted efforts to produce direct inhibitors have largely failed, earning KRAS the title of “undruggable”. Recent efforts to produce subtype specific inhibitors have been more successful, and several KRASG12C inhibitors have reached clinical trials, including adagrasib and sotorasib, which have shown early evidence of efficacy in patients. Lessons from other inhibitors of the RAS pathway suggest that the effect of these drugs will be limited in vivo by the development of drug resistance, and pre-clinical studies of G12C inhibitors have identified evidence of this. In this review we discuss the current evidence for G12C inhibitors, the mechanisms of resistance to G12C inhibitors and potential approaches to overcome them. We discuss possible targets of combination therapy, including SHP2, receptor tyrosine kinases, downstream effectors and PD1/PDL1, and review the ongoing clinical trials investigating these inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 2×
“KRAS mutations are most frequently found in epithelial cancers such as pancreatic, colorectal and lung adenocarcinomas [5,6].”
BackgroundMethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“These compounds rely on mutant cysteine for binding, disrupting Switch-I/II and converting KRAS preference from GTP to GDP, thus holding KRAS in the inactive GDP bound state [29].”
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 7×
“[27] found that AMG-510 led to a pro-inflammatory tumour microenvironment and acted synergistically with immune checkpoint inhibitors.”
BackgroundInfluentialUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 13×
“GEFs stimulate the dissociation of GDP and subsequent association of GTP, activating RAS proteins, while GAPs act to accelerate intrinsic GTP hydrolysis, converting RAS to its inactive state [2,3].”
BackgroundInfluentialRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“GEFs stimulate the dissociation of GDP and subsequent association of GTP, activating RAS proteins, while GAPs act to accelerate intrinsic GTP hydrolysis, converting RAS to its inactive state [2,3].”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · cited 1×
“9 months in patients with NSCLC receiving standard 2nd or 3rd line chemotherapy [36]).”
BackgroundSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · cited 1×
“Missense mutations at codons 12 and 13 are thought to limit interaction of GAP proteins with the GTPase site of RAS proteins, preventing their hydrolysis to an inactive state [8].”
BackgroundEngelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 3×
“Targeting CDK would theoretically increase the effects of G12C inhibitors by maximising cell cycle arrest, and combination with the CDK4/6 inhibitor palbociclib has been shown to have synergistic effects with ARS-1620 and adagrasib [28,74].”
BackgroundRegulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973 · cited 3×
“KRAS is overwhelmingly the most commonly mutated RAS isoform in cancer, comprising 85% of oncogenic RAS mutations [1].”
BackgroundInfluentialSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875 · cited 1×
“Despite the high prevalence of KRAS mutations in pancreatic adenocarcinoma, G12C is a minor subtype in this cohort (~1%) [22,24,25].”
BackgroundSingh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 2×
“An exception is KRASG13D, which shows significantly elevated intrinsic exchange activity compared to wild-type RAS, and therefore may have a short-lived GDP-bound state [31].”
BackgroundKRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 1×
“Other studies have identified amplification of the transcriptional coactivator YAP1 as a means of bypassing KRAS inhibition in cancer cell lines [44,45].”
BackgroundAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585 · cited 1×
“Extensive research has also been channeled into the development of inhibitors that act downstream of RAS, but so far these have largely failed to show significant clinical benefits, either due to acquired resistance to the drug or toxicity limiting the maximum tolerated dose [20,21].”
BackgroundInfante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552 · cited 1×
“Clinical attempts to target the MAPK pathway have previously focused on MEK, but disappointingly these inhibitors have proven to have limited therapeutic activity in KRAS-mutant lung cancer patients [47].”
BackgroundRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543 · cited 7×
“[57] identified a heterogenous response of KRASG12C mutant cancer cells to G12C inhibition with ARS-1620.”
BackgroundResultInfluentialEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504 · cited 1×
“In an effort to understand this difference it has been shown that, in comparison to NSCLC lines, CRC cell lines failed to demonstrate sustained ERK inhibition after treatment with sotorasib, and that G12C-mutant CRC cell lines retained their dependency on EGFR for downstream signalling [68].”
ResultVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · cited 6×
“Furthermore, this study identified no single RTK that was critical for all KRASG12C models but found that co-inhibition of SHP2 resulted in universal and sustained inhibition of feedback reactivation [58].”
BackgroundResultInfluentialShimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · cited 1×
“However, the increased efficacy appears to come at the expense of greater toxicity, which may limit the usefulness of this combination therapy in the clinic [71,72].”
BackgroundNichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415 · cited 1×
“SHP2 inhibition has also been demonstrated to have single agent efficacy in pre-clinical models with oncogenic mutations in the RAS/RAF/MEK/ERK pathway [62].”
BackgroundThe molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
Dance, M., Montagner, A., Salles, J.-P., Yart, A., & Raynal, P. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.002 · Cited by 361 · cited 1×
“SHP2 is a phosphatase that mediates signaling from multiple RTKs to the RAS pathway, and as such offers an attractive target for KRASG12C combination therapy [59].”
BackgroundBlumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347 · cited 1×
“RAS proteins play a vital role in cellular proliferation, differentiation and survival, through their association with multiple downstream pathways, the best characterised of which are the Raf/Mek/Erk and PI3K/PTEN/Akt pathways [4].”
BackgroundJänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335 · cited 1×
“The large multinational randomised control trial SELECT-1 compared docetaxel alone or in combination with the MEK inhibitor selumetinib in 510 patients with KRAS-mutant NSCLC, finding no significant difference in progression-free or overall survival [48].”
MethodSelf-citationSHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315 · cited 2×
“found that G12C/SHP2 inhibition increased CD8+ T cell infiltration into the tumour microenvironment, and triple therapy with PD-1 inhibitors resulted in greater tumour regression in PDAC murine models [60].”
BackgroundKRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · cited 1×
“The phenomenon of acquired resistance to targeted therapy has frequently been noted with downstream inhibitors of the RAS pathway, examples of which are too numerous to comprehensively cover here but have been reviewed elsewhere [10,12,46].”
BackgroundMukhopadhyay, S., Goswami, D., Adiseshaiah, P. P., Burgan, W., Yi, M., Guerin, T. M., Kozlov, S. V., Nissley, D. V., & McCormick, F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1363 · Cited by 279 · cited 1×
“Glutamine depletion and use of glutaminase inhibitors sensitises PDAC cells to the chemotherapeutic agent gemcitabine [77].”
BackgroundKRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259 · cited 6×
“As seen with downstream inhibitors, blockade of RTK overcame resistance in a subset of models, however, PI3K pathway inhibition appeared to be more broadly effective [56].”
BackgroundInfluentialTargeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239 · cited 1×
“Extensive research has also been channeled into the development of inhibitors that act downstream of RAS, but so far these have largely failed to show significant clinical benefits, either due to acquired resistance to the drug or toxicity limiting the maximum tolerated dose [20,21].”
BackgroundAdjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.075 · Cited by 219
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203 · cited 1×
“[73] found that co-targeting mTOR/IGF1R and either MEK or KRASG12C showed efficacy in mouse models of KRAS-mutant lung cancer, with less toxicity noted in the G12C inhibitor combination.”
BackgroundKRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer
Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · cited 1×
“Even with complete KRAS inhibition, a subset of KRAS-mutant PDAC cells remain viable, and a significant majority of these demonstrate PI3K-dependent MAPK signalling and sensitivity to MAPK pathway inhibitors [43].”
BackgroundKRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175 · cited 1×
“Targeting CDK would theoretically increase the effects of G12C inhibitors by maximising cell cycle arrest, and combination with the CDK4/6 inhibitor palbociclib has been shown to have synergistic effects with ARS-1620 and adagrasib [28,74].”
BackgroundCombinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167 · cited 1×
“This synergistic effect was the most significant of all TNO155 combinations tested in the study and was also postulated to be secondary to increased GDP occupancy of KRAS [66].”
BackgroundKitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31076-5 · Cited by 140
Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0852 · Cited by 90 · cited 1×
“Inhibition of SHP2 has been investigated with other inhibitors of the RAS/MAPK pathway and shown to overcome RTK driven acquired resistance to MEK inhibition [60,61].”
BackgroundSTK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
Shire, N. J., Klein, A. B., Golozar, A., Collins, J. M., Fraeman, K. H., Nordstrom, B. L., McEwen, R., Hembrough, T., & Rizvi, N. A. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238358 · Cited by 85
Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31077-7 · Cited by 77
Ou, S. I., Koczywas, M., Ulahannan, S., Janne, P., Pacheco, J., Burris, H., McCoach, C., Wang, J. S., Gordon, M., Haura, E., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.041 · Cited by 73
Saqcena, M., Mukhopadhyay, S., Hosny, C., Alhamed, A., Chatterjee, A., & Foster, D. A. (2015) · Oncogene · doi:10.1038/onc.2014.207 · Cited by 67 · cited 1×
“The reliance on Gln creates a Gln dependent G1 cell cycle checkpoint, which KRAS mutant cancer cells are able to bypass in states of Gln depletion, instead arresting in S/G2 [75].”
BackgroundGermline and sporadic cancers driven by the RAS pathway: parallels and contrasts
Dunnett-Kane, V., Burkitt-Wright, E., Blackhall, F. H., Malliri, A., Evans, D. G., & Lindsay, C. R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.291 · Cited by 66
Self-citationOvercoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Resistance looms for KRASG12C inhibitors
Hata, A. N., & Shaw, A. T. (2020) · Nature Medicine · doi:10.1038/s41591-020-0765-z · Cited by 51
Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond
Klempner, S. J., & Hata, A. N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1255 · Cited by 15 · cited 1×
“Finally, although adaptive signalling pathways appear important in experimental models, it is unclear what the relevance of this will be in patients [78].”
Background
Research works printed but not linked: 17
- Pakkala, 2018, Personalized therapy for lung cancer: Striking a moving target, JCI Insight, 3, 120858, 10.1172/jci.insight.120858 · DOI · Paper page
- Wang, 2012, Ras inhibition via direct Ras binding—Is there a path forward?, Bioorganic Med. Chem. Lett., 22, 5766, 10.1016/j.bmcl.2012.07.082 · DOI · Paper page
- Lindsay, 2018, KRAS: Reasons for optimism in lung cancer, Eur. J. Cancer, 99, 20, 10.1016/j.ejca.2018.05.001 · DOI · Paper page
- Ahearn, 2011, Regulating the regulator: Post-translational modification of RAS, Nat. Rev. Mol. Cell Biol., 13, 39, 10.1038/nrm3255 · DOI · Paper page
- Brunner, 2003, Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations, Cancer Res., 63, 14522880
- Kohl, 1995, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice, Nat. Med., 1, 792, 10.1038/nm0895-792 · DOI · Paper page
- Heymach, 2004, Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer, Ann. Oncol., 15, 1187, 10.1093/annonc/mdh315 · DOI
- Ho, 2018, Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations, Ann. Oncol., 29, viii373, 10.1093/annonc/mdy287.002 · DOI
- Burrows, 2020, Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma, Eur. J. Cancer, 138, S43, 10.1016/S0959-8049(20)31191-6 · doi:10.1016/s0959-8049(20)31191-6
- Lindsay, 2019, Direct Ras G12C inhibitors: Crossing the rubicon, Br. J. Cancer, 121, 197, 10.1038/s41416-019-0499-1 · DOI · Paper page
- Hayashi, 2013, Postprogression Survival in Patients with Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy, Clin. Lung Cancer, 14, 261, 10.1016/j.cllc.2012.09.006 · DOI · Paper page
- Franke, 2008, PI3K/Akt: Getting it right matters, Oncogene, 27, 6473, 10.1038/onc.2008.313 · DOI · Paper page
- Little, 2011, Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells, Sci. Signal., 4, ra17, 10.1126/scisignal.2001752 · DOI · Paper page
- Bendell, 2020, Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling, Eur. J. Cancer, 138, S8, 10.1016/S0959-8049(20)31089-3 · DOI
- Alagesan, 2015, Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer, Clin. Cancer Res., 21, 396, 10.1158/1078-0432.CCR-14-1591 · DOI · Paper page
- Juric, 2014, A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors, J. Clin. Oncol., 32, 9051, 10.1200/jco.2014.32.15_suppl.9051 · DOI · Paper page
- Foster, 2014, Metabolic vulnerability of KRAS-driven cancer cells, Mol. Cell. Oncol., 1, e963445, 10.4161/23723548.2014.963445 · DOI
Cited by
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Reck, M., Carbone, D. P., Garassino, M., & Barlesi, F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.001 · Cited by 326
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-22668-1 · Cited by 93
“Nineteen (19) compounds were selected and further subjected to docking using GLIDE docking suit incorporated in Schrödinger with an extra precision (XP).”
Method
Metadata
- Authors
- Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-05
- Volume
- 13
- Issue
- 1
- Pages
- 151
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3119145039
- Cited by
- 117
- References
- 59
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Cancer Research UK (A25254, A20465)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.